Kannabis lääkkeenä – kirjallisuusviitteitä

David W. Pate

• Guimares, F.S. et al., 1990. Anxiolytic effect of cannabidiol
  in the elevated plus-maze. Psychopharmacology 100: 558-559.
• Guimares, F.S. et al., 1994. Anxiolytic effect of cannabidiol
  derivatives in the elevated plus-maze. Gen. Pharmac. 25: 161-164.
• Zuardi, A.W. et al., 1982. Action of cannabidiol on the anxiety
  and other effects produced by delta-9-THC in normal subjects. Psychopharmacology
  76: 245-250.
• Zuardi, A.W. et al., 1991. Effects of cannabidiol in animal
  models predictive of antipsychotic activity. Psychopharmacology
  104: 260-264.
• Zuardi, A.W. et al., 1993. Effects of ipsapirone and cannabidiol
  on human experimental anxiety. J. Psychophamacol. 7: 82-88.

• Gong, H. et al., 1984. Acute and subacute bronchial effects
  of oral cannabinoids. Clin. Pharm. Ther. 35: 26-32.
• Graham, J.D.P., 1986. The bronchodilator action of cannabinoids. In
  Cannabinoids as Therapeutic Agents, R. Mechoulam, Ed., CRC Press, Boca
  Raton, Florida, pp. 147-158.
• Hartley, J.P., et al., 1978. Bronchodilator effect of delta-9-THC.
  Br. J. Clin. Pharmacol. 5: 523.
• Karniol, I.G., et al., 1974. Cannabidiol interferes with the
  effects of delta-9-tetrahydrocannabinol in man. Eur. J. Pharmac.
  28: 172.
• Tashkin, D., et al., 1973. Acute pulmonary physiologic effects
  of smoked marijuana and oral delta-9-tetrahydrocannabinol in healthy young
  men. New Engl. J. Med. 289: 336-341.
• Tashkin, D., et al., 1976. Acute effects of smoked marijuana
  on airway dynamics in spontaneous and experimentally induced bronchial
  asthma. In The Pharmacology of Marijuana, Braude and Szara, Eds.,
  Raven Press, New York, pp. 785-799.
• Vachon, L. et al., 1976. Airways respons to aerosolized delta-9-THC
  preliminary report. In The Therapeutic Potential of Marijuana, Cohen,
  S. and Stillman, R.C., Eds., Plenum Press, New York, p. 111.
• Vachon, L. et al., 1976. Airways response to micro-aerosolized
  delta-9-THC. Chest 70: 444.
• Williams, S.J. et al., 1976. Bronchodilator effect of delta-9-THC
  administered by aerosol to asthmatic patients. Thorax 31: 720.

• Ames, F.R. and Cridland, S., 1986. Anticonvulsant effect of cannabidiol.
  S. Afr. Med. J. 69: 14.
• Consroe, P.F. et al., 1975. Anticonvulsant nature of marihuana
  smoking. J.A.M.A. 234: 306-307.
• Cunha, J.M. et al., 1980. Chronic administration of cannabidiol
  to healthy volunteers and epileptic patients. Pharmacology 21: 175-185.
• Davis, J.P. and Ramsey, H.H., 1949. Anti-epileptic action of marijuana-active
  substances. Fed. Proc. Am. Soc. Exp. Biol. 8: 284.
• Feeney, D. 1976. Marihuana use among epileptics. J.A.M.A. 235:
  1105.
• Karler, R. and Turkanis, S.A. 1981. The cannabinoids as potential antiepileptics.
  J. Clinical Pharmacology 21: 437S-448S.
• Karler, R. et al., 1973. The anti-convulsant activity of cannabidiol
  and cannabinol. Life Sci. 13: 1527-1531.
• Karler, R. et al., 1984. Interaction between delta-9-tetrahydrocannabinol
  and kindling by electrical and chemical stimulation in mice. Neuropharmacology
  23: 1315-1320.
• Karler, R. et al., 1989. Pentylenetetrazole kindling in mice.
  Neuropharmacology 28: 775-780.
• Karler, R. et al., 1974. Anticonvulsant properties of delta-9-tetrahydrocannabinol
  and other cannabinoids. Life Sci. 15: 931-947.
• Karler, R. et al., 1986. Prolonged CNS hyperexcitability in
  mice after a single exposure to delta-9-tetrahydrocannabinol. Neuropharmacology
  25: 441-446.
• Karler, R. and Turkanis, S., 1976. The anti-epileptic potential of
  the cannabinoids. In The Therapeutic Potential of Marijuana, Cohen
  and Stillman, Eds., Plenum Press, New York, pp. 383-396.
• Turkanis, S. et al., 1974. Anti-convulsant properties of cannabinol.
  Res. Comm. Chem. Pathol. Pharmacol. 8: 231-246.

• Colasanti, B.K. 1986. Review: Ocular hypotensive affect of marihuana
  cannabinoids: correlate of central action or separate phenomenon. J.
  Ocular Pharmacology 2(3): 295-304.
• Colasanti, B.K. et al., 1984. Ocular hypotension, ocular toxicity,
  and neurotoxicity in response to marijuana extract and cannabidiol. Gen.
  Pharmacol. 15: 479.
• Colasanti, B.K. et al., 1984. Intraocular pressure, ocular toxicity
  and neurotoxicity after administration of delta-9-tetrahydrocannabinol
  or cannabichromene. Exp. Eye Res. 38: 63.
• Colasanti, B.K. et al., 1984. Intraocular pressure, ocular toxicity
  and neurotoxicity after administration of cannabinol or cannabigerol. Exp.
  Eye Res. 39: 231-259.
• Crawford, W. & Merritt, J.C., 1979. Effects of tetrahydrocannabinol
  on arterial and intraocular hypertension. Int. J. Clin. Pharmacol. Biopharmacol.
  17: 191-196.
• Green, K. and McDonald, T.F., 1987. Ocular toxicology of marijuana:
  an update. J. Toxicol.-Cut. and Ocular Toxicol. 6: 309-334.
• Hepler, R.S. and Frank, I.M. 1971. Marihuana smoking and intraocular
  pressure. J.A.M.A. 217: 1392.
• Hepler, R.S. et at., 1976. Ocular effects of marijuana smoking. In
  The Pharmacology of Marijuana, Braude, M.C., and Szara, S., Eds., Raven
  Press, New York, p. 813.
• Levitt, M. et at., 1981. Physiologic observations in a controlled clinical
  trial of the antiemetic effectiveness of 5, 10, and 15 mg of delta-9-tetrahydrocannabinol
  in cancer chemotherapy: ophthalmologic implications. J. Clin. Pharmacol.
  21: 103S.
• Merritt, J.C. et at., 1980. Effect of marijuana on intraocular and
  blood pressure in glaucoma. Ophthalmology 87: 222.
• Merritt, J.C. et at., 1981. Topical delta-9-tetrahydrocannabinol in
  hypertensive glaucomas. J. Pharm. Pharmacol. 33: 40-41.
• Merritt, J.C. et at., 1981. Topical delta-9-tetrahydrocannabinol and
  aqueous dynamics in glaucoma. J. Clin. Pharmacol. 21: 467S-471S.
• Merritt, J.C. et at., 1980. Oral delta-9-tetrahydrocannabinol in heterogenous
  glaucomas. Ann. Opthalmol. 12: 8.
• Merritt, J.C. et at., 1982. Topical delta-9-tetrahydrocannabinol as
  a potential glaucoma agent. Glaucoma 4: 253-255.
• Shapiro, D., 1974. The ocular manifestation of the cannabinoids. Ophthalmologia
  168: 366-369.

• Barret, M.L. et al., 1985. Isolation from Cannabis sativa
  L. of Cannflavon-a novel inhibitor or prostaglandin production. Biochem.
  Pharmacol. 34: 2019.
• Burstein, S.H. et al., 1989. Antagonism to the actions of platelet
  activating factor by a nonpsychoactive cannabinoid. J. Pharmacol. Exp.
  Therap. 251: 531-535.
• Evans, A.T. et al., 1987. Actions of Cannabis constituents on
  enzymes or arachidonate metabolism: anti-inflammatory potential. Biochem.
  Pharmacol. 36: 2037-2040.
• Formukong, E.A. et al., 1987. Cannabinoids, the active constituents
  of Cannabis sativa L. inhibit both human and rabbit platelet aggregation.
  Br. J. Pharmacol. 92(S): 601.
• Formukong, E.A. et al., 1989. The inhibitory effects of cannabinoids,
  the active constituents of Cannabis sativa L. on human and rabbit
  platelet aggregation. J. Pharm. Pharmacol. 41: 705-709.
• Formukong, E.A. et al., 1988. Analgesic and anti-inflammatory
  activity of constituents of Cannabis sativa L. Inflammation
  12: 361-371.
• Sofia, R.D. et al., 1973. Antiedemic and analgesic properties
  of delta-9-tetrahydrocannabinol compared with three other drugs. Eur.
  J. Pharmacol. 35: 7-16.
• Sofia, R.D. et al., 1974. Comparative anti-phlogistic activity
  of delta-9-tetrahydrocannabinol, hydrocortisone and aspirin in various
  rat paw edema models. Life Sci. 15: 251-260.

• Blevins, R.D. and Damie, M.R., 1980. The effect of delta-9-THC on Herpes
  simplex virus replication. J. Gen. Virol. 49: 427.
• Dahiya, M.S. and Jain, G.C., 1977. Antibacterial activity of cannabidiol
  and tetrahydrocannabinol. Indian Drugs Pharm. Ind. 12: 31-34.
• ElSohly, H.N. et al., 1982. Synthesis and antimicrobial activity
  of certain cannabichromene and cannabigerol related compounds. J. Pharm.
  Sci. 71: 1319-1323.
• Ferenczy, L. et at., 1958. An antibacterial preparatum from hemp (Cannabis
  sativa L.). Naturwissenschaften. 45: 188.
• Grlic, L., 1962. A comparative study on some chemical and biological
  characteristics of various samples of Cannabis resin. Bull. Narc.
  14: 37-46.
• Kabelik, J. et al., 1960. Cannabis as a medicament. Bull.
  Narc. 12: 5.
• Krejci, Z., 1958. Hanf (Cannabis sativa)- Antibiotisches heilmittel.
  2. Methodik und ergebnisse der bakteriologischen untersuchungen und vorlaufige
  klinische erfahrungen. Pharmazie 13: 155-164.
• Krejci, Z., 1970. Changes with maturation in amounts of biologically
  interesting substances of Cannabis. In The Botany and Chemistry
  of Cannabis, Proc. Conf., Joyce, C.R.B., Ed., J. & A. Churchill,
  London, pp. 49-55.
• Krejci, Z., 1961. The problem of substances with antibacterial action:
  Cannabis effect. Casop. Lek. Cesk. 43: 1341-1354.
• Martinec, T. and Felklova, M., 1959. Einfluss veraschiedener dungung
  suf die antibakterielle aktivitat des hanfes, Cannabis sativa L.
  Pharmazie 14: 276-279.
• Martinec, T. and Felkiova, M., 1959. Veranderungen der antibakteriellen
  aktivitat im verlaus der individuellen entwicklung des hanfes (Cannabis
  sativa L.). Pharmazie 14: 279-281.
• Radosevic, A. et al., 1962. Antibiotic activity of various types
  of Cannabis resin. UN Secretariat Doc. ST/SOA/SER.S/6. 9
  Jan. 25.
• Radosevic, A. et al., 1962. Antibiotic activity of various types
  of Cannabis resin. Nature 195: 1007-1009.
• Van Kingeren, B. and Ten Ham, M., 1976. Antibacterial activity of delta-9-THC
  and cannabidiol. Ant. van Leeuw. J. Microbiol. Serol. 42: 9.

• Consroe, P. et al., 1986. Open label evaluation of cannabidiol
  in dystonic movement disorders. Int. J. Neurosci. 30: 277-282.
• Consroe, P. et al., 1991. Controlled clinical trial of cannabidiol
  in Huntington's disease. Pharmacol. Biochem. Behav. 40: 701-708.
• Frankel, J.P. et al., 1990. Marijuana for Parkinsonian tremor.
  J. Neurol. Neurosurg. Psychiatry 53: 436.
• Hemming, M. and Yellowle, P.M., 1993. Effective treatment of Tourette's-Syndrome
  with marijuana. J. Psychopharmacol. 7: 389-391.
• Moss, D.E. et al., 1989. Nicotine and cannabinoids as adjuncts
  to neuroleptics in the treatment of Tourette syndrome and other motor disorders.
  Life Sci. 44: 1521-1525.
• Ruchman, M.C., 1988. Role of cannabidiol in the medical treatment of
  Meige's syndrome. Ear Nose Throat J. 67: 919.
• Sandyk, R. et al., 1986. Cannabidiol in dystonic movement disorders.
  Psychiatry Res. 18: 291.
• Snider, S.R. and Consroe, P., 1984. Treatment of Meige syndrome with
  cannabidiol. Neurology 34(S1): 147.
• Snider, S.R. and Consroe, P., 1985. Beneficial and adverse effects
  of cannabidiol in a Parkinson patient with sinemet-induced dystonic dyskinesia.
  Neurology 35(S1): 201.

• Clifford, David B., 1983. Tetrahydrocannabinol for tremor in Multiple
  Sclerosis. Ann. Neurol. 13: 669-671.
• Dunn, M. and Davis, R., 1974. The perceived effects of marijuana on
  spinal cord injured males. Paraplegia 12: 175.
• Elkin, R. et al., 1987. Delta-9-tetrahydrocannabinol: a novel
  treatment of inflammatory demyelination. Fed. Proc. 46: 1378.
• Greenberg, H.S. et al., 1990. Marijuana and its effect on postural
  stability in Multiple Sclerosis patients with controls. Neurology
  40(S1): 259.
• Hanigan, W.C. et al., 1986. The effects of delta-9-tetrahydrocannabinol
  on human spasticity. J. Am. Soc. Clin. Pharmacol. 39: 198.
• Lyman, W.D. et al., 1989. Delta-9-tetrahydrocannabinol: A novel
  treatment for experimental autoimmune encephalitis. J. Neuroimmunol.
  23: 73-82.
• Malec, J. et al., 1982. Cannabis effect on spasticity
  in spinal cord injury. Arch. Phys. Med. Rehab. 63: 116.
• Mauer, M. et al., 1990. Delta-9-tetrahydrocannabinol shows anti-spastic
  and analgesic effects in a single case double-blind trial. Eur. Arch.
  Psychiatry Clin. Neurosci. 240: 1-4.
• Meinck, H.M. et al., 1989. Effect of cannabinoids on spasticity
  and ataxia in Multiple Sclerosis. J. Neurol. 236: 120-122.
• Petro, D. 1980. Marihuana as a therapeutic agent for muscle spasm or
  spasticity. Psychosomatics 21: 81-85.
• Petro, D. and Ellenberger, C., Jr., 1981. Treatment of human spasticity
  with delta-9-tetrahydrocannabinol. J. Clin. Pharmacol. 21: 413S-416S.
• Truong, X.T. and Hanigan, W.C., 1986. Effect of delta-9-tetrahydrocannabinol
  on electromyographic measurements in human spasticity. J. Am. Soc. Clin.
  Pharmacol. Therap. 39: 232.
• Ungerleider, J.T. et al., 1987. Delta-9-tetrahydrocannabinol
  in the treatment of spasticity associated with Multiple Sclerosis. Adv.
  Alcohol Subst. Abuse 7: 39-50.

• Burstein, S. et al., 1984. Stimulation of sphingomyelin hydrolysis
  by cannabidiol in fibroblasts from a Niemann-Pick patient. Biochem.
  Biophys. Res. Comm. 121: 168-173.

• Bhargava, H.N., 1976. Effect of some cannabinoids on naloxone-precipitated
  abstinence in morphine-dependent rats. Psychopharmacology 49: 267.
• Carder, B., 1975. Blockage of morphine abstinence by delta-9-THC. Science
  190: 590.
• Hine, B. et al., 1975. Morphine-dependent rats: blockage of
  precipitated abstinence by THC. Science 187: 443.
• Mikuriya, T., 1970. Cannabis substitution: an adjunctive tool
  in the treatment of alcoholism. Med. Times 98: 187-191.
• Rosenberg, C., 1976. The use of marijuana in the treatment of alcoholism.
  In The Therapeutic Potential of Marijuana, Cohen and Stillman, Eds.,
  Plenum Press, New York, pp. 173-185.
• Rosenberg, C.M. et al., 1978. Cannabis in the treatment
  of alcoholism. J. Stud. Alcohol 39: 155.
• Scher, J., 1971. Marijuana as an agent in rehabilitating alcoholics.
  Am. J. Psychiatry 127: 971-972.

• Harris, L., 1976. Analgesic and antitumor potential of the cannabinoids.
  In The Therapeutic Potential of Marijuana, Cohen and Stillman, Eds.,
  Plenum Press, New York, pp. 299-305.
• Milstein, S.L. et al., 1975. Marijuana-produced changes in pain
  tolerance: experienced and non-experienced subjects. Int. Pharmacopsychiatry
  10: 177-182.
• Noyes, S.J., Jr. and Baram, D.A., 1974. Cannabis analgesia.
  Compr. Psychiatry 15: 5.
• Noyes, S.J., Jr. et al., 1975. The analgesic properties of delta-9-tetrahydrocannabinol
  and codeine. Clin. Pharmacol. Ther. 18: 84-89.
• Noyes, S.J., Jr. et al., 1975. The analgesic effect of delta-9-tetrahydrocannabinol.
  J. Clin. Pharamacol. 15: 139.
• Volfe, Z. et al., 1985. Cannabinoids block release of serotonin
  from platelets induced by plasma from migraine patients. Int. J. Clin.
  Pharm. Res. 5: 243-246.
• Zeidenberg, P., et al., 1973. Effect of oral administration
  of delta-9-tetrahydrocannabinol on memory, speech and perception of thermal
  stimulation: results with four normal human subjects. Preliminary report.
  Compr. Psychiatry 14: 549.

• Bateman, D.N., 1987. Delta-9-tetrahydrocannabinol and gastric emptying.
  Br. J. Clin. Pharmacol. 15: 139.
• Douthwaite, A.H., 1947. Choice of drugs in the treatment of duodenal
  ulcer. Br. Med. J. 43: 4514.
• Nalin, D.R. et al., 1978. Cannabis, hypochlrohydria and
  cholera. Lancet 2: 859.
• Sofia, R.D. et al., 1978. Evaluation of antiulcer activity of
  delta-9-tetrahydrocannabinol in the Shay rat test. Pharmacology
  17: 173.